查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1676681

动物抗生素市场按类别、动物类型、最终用户和治疗领域划分 - 2025-2030 年全球预测

Veterinary Antibiotics Market by Class, Animal Type, End-User, Therapeutic Areas - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计 2023 年兽用抗生素市场价值将达到 25.8 亿美元，到 2024 年将以 9.01% 的复合年增长率增长至 28.1 亿美元，到 2030 年将达到 47.3 亿美元。

主要市场统计数据
基准年 2023 年 25.8亿美元
预计 2024 年 28.1亿美元
预测年份 2030 47.3亿美元
复合年增长率（%） 9.01％

兽用抗生素持续改变动物保健和治疗的模式，在保护动物和人类族群方面发挥着至关重要的作用。执行摘要对兽用抗生素市场的现状和发展趋势进行了深入分析，强调了新出现的抗生素抗药性、监管压力和不断变化的市场动态所带来的挑战和机会。分析强调了严谨的研究和有针对性的调查方法对于掌握快速变化的行业的复杂性的重要性。在当今竞争激烈的全球环境中，从药物开发商到动物保健专业人士的相关人员都认识到需要将他们的策略与深入的、资料主导的洞察力相结合。本报告的目的是提供市场动态的全面概述，同时提供可行的见解，以支援在复杂性和范围不断增加的领域的策略决策。

本报告首先从兽用抗生素的历史角度开始，然后逐步检验重新定义市场预期的突破性变化和技术创新。坚持高标准的功效、安全性和环境保护的重要性贯穿整个叙述，以确保行业领导者能够充分应对当代问题，例如监管重新调整、适应全球供应链和抗生素管理的新需求。这项详尽的介绍为深入探讨现代动物保健这一高度活跃且重要的市场奠定了基础。

兽用抗生素领域的变革

近年来，动物抗生素市场经历了一场变革，从根本上改变了专业人士应对长期存在和新兴挑战的方式。技术创新、监管变化和不断发展的市场动态正在推动更有针对性和更有效的抗生素疗法的发展。

最大的变化之一是向精准兽医医学的转变。诊断技术和基因分析的进步提高了我们针对特定细菌病原体和感染疾病制定抗生素治疗的能力。这种精准的方法不仅可以改善治疗效果，而且在限制广泛和经验性使用抗生素而产生抗药性方面发挥关键作用。

不断变化的法律规范也在市场转型中发挥不可或缺的作用。对畜牧业生产中抗生素使用的审查越来越严格，加上严格的安全通讯协定，导致了强调负责任使用抗生素的新指南的製定。这些监管发展促使行业相关人员迅速适应并投资研发，以生产出符合更高标准同时保持治疗效果的新配方。

此外，市场动态受到消费者意识不断增强和对伴同性动物健康日益关注的影响。随着宠物饲主对他们所爱的动物的治疗越来越谨慎，製药公司已经启动了教育和培训兽医专业人员的计划，以确保抗生素处方实践符合最新的研究结果和负责任的给药通讯协定。

这一转型阶段得到了永续性的大力支持，特别是旨在减少环境残留物和限制对生态系统影响的技术创新的发展。诊断技术的增强、法规的更全面以及消费者意识的不断增强，共同创造了一个越来越重视精准性、安全性和永续实践的市场，确保兽用抗生素的使用既有科学依据又受到道德监督。

按类别、物种、最终用户和治疗领域分類的关键细分见解

对动物抗生素市场的详细细分提供了对该行业的多方面了解，并揭示了复杂的模式和成长机会。市场从多个角度进行细分，包括抗生素类别、治疗的动物类型、最终用户设定和治疗领域概述。透过根据这些不同的细分标准研究市场，我们可以确定能够做出更有针对性和更有效的策略决策的趋势。

考虑到抗生素的分类，我们发现已经全面调查了各种药物类别，包括Aminoglycosides、酰胺醇类、头孢菌素类、氟喹诺酮类、Fluoroquinolones、其他奎诺酮、青霉素类、多粘菌素类、磺胺类药物、四环霉素和甲氧芐啶。这些药物类别进一步细分为Aminoglycosides，例如Amikacin、安普霉素、庆大霉素、卡那霉素和新霉素，每种药物都具有治疗抗药性感染疾病的独特特性。类似地，酰胺醇类进一步细分，包括阿齐丹酚、氯霉素、氟苯尼考、甲硫霉素和甲砜霉素等化合物。同样，头孢菌素类药物也被细分，以探索头孢氨芐、头孢洛铵、头孢唑林、头孢维星、头孢噻呋和头孢曲松等特定的市场利基，从而可以更有针对性地应对抗药性细菌。并行分析了以下Fluoroquinolones抗生素：Ciprofloxacin、达氟沙星、二氟沙星、恩诺沙星、诺氟沙星和奥比沙星；以及大环内酯类抗生素：阿奇霉素、克拉霉素、红霉素、加米霉素、螺旋霉素、替米考星、泰拉霉素和泰乐菌素。同样，其他奎诺酮抗菌剂（例如西诺沙星、萘啶酸、奥索利酸、吡哌酸、罗索沙星等）的组合也在接受研究，以更深入地了解其市场潜力。将青霉素分为阿莫西林、Ampicillin、氯唑西林、苯唑西林、青霉素 G、青霉素 V 等子类别，可以获得推动产品差异化的有针对性的见解。多粘菌素类又分为粘菌素/多粘菌素E和多粘菌素B，磺胺类药物又分为磺胺嘧啶、磺胺甲基嘧啶、磺胺甲二唑、磺胺甲噁唑和柳氮磺吡啶。对四环霉素进行了分析，包括其变体，例如四环霉素、强力霉素、四环霉素和四环霉素，而对甲氧芐啶类药物进行了细分，以探索组合，例如甲氧芐啶加磺胺二甲嘧啶、甲氧芐啶-磺胺嘧啶、甲氧芐啶-磺胺二甲胺啶-甲氧芐啶-甲磺胺啶甲胺啶。

除了复杂的药物分类外，按动物类型分析市场可以根据所治疗动物的特征揭示独特的趋势。市场传统上分为两个主要部分：伴同性动物和牲畜。在伴同性动物领域，治疗主要针对家养宠物，特别是狗和猫，治疗方法必须在微妙的生理环境中平衡功效和安全性。另一方面，畜牧业涵盖的动物种类更广泛，包括牛、家禽、绵羊、山羊和猪。这些群体需要量身定制的治疗策略，以反映不断变化的畜牧业实践、特定物种的生理学以及确保食物链安全的重要性。

此外，基于最终用户偏好的细分可以深入了解塑造市场生态系统的通路动态。专业化动物生产设施的使用是为了满足规模和效率的需求。这与家庭宠物饲主注重个人化照护的消费者主导的使用模式相得益彰。兽医诊所的角色仍然至关重要，这些机构充当先进研究和实际应用之间的纽带，为创新抗生素疗法创造了肥沃的土壤。

最后，探索市场内的治疗领域凸显了与兽用抗生素相关的应用广度。评估涵盖了一系列治疗挑战，包括皮肤感染疾病、胃肠道感染疾病、生殖系统感染疾病、呼吸道感染疾病、软组织和伤口感染疾病、全身性感染疾病和尿道感染。将这些治疗领域与不同动物群体的特定需求联繫起来，使相关人员能够根据经济和临床指标定制干预措施，确保每个应用领域都透过有针对性的研究、及时的创新和客製化的治疗方案得到最佳实现。

摘要，细分市场揭示了兽用抗生素市场的复杂性和层次性。这种详细而结构化的方法提供了对宏观和微观层面趋势的深入了解，为精准的市场定位和识别每个子区隔中的潜在商机奠定了基础。

目录

第 1 章 简介

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 市场动态
    • 驱动程式
      • 由于对乳製品和肉品的需求增加，牲畜数量增加
      • 动物感染疾病通用和其他感染疾病的盛行率不断上升
      • 世界各地的宠物友谊日益增多，人类也变得越来越有人性。
    • 限制因素
      • 兽医疾病抗原抗生素抗药性问题日益令人担忧
    • 机会
      • 药物输送系统的进步提高了兽用抗生素的功效和安全性。
      • 开发具有新机制的新型抗生素的成长潜力
    • 任务
      • 各地关于兽用抗生素禁用问题
  • 市场区隔分析
    • 类别：各国对用于治疗牛和鱼的呼吸道疾病的氨苯丙醇的需求日益增加。
    • 动物类型：使用兽用抗生素来确保牲畜食品供应链的安全以及农民的经济稳定
    • 最终用户：动物抗生素用于动物生产设施，以防止疾病爆发并确保最佳生长率。
    • 治疗领域：透过使用兽用抗生素预防呼吸道感染疾病并维持畜群健康，
  • 波特五力分析
  • PESTEL 分析
    • 政治的
    • 经济
    • 社会的
    • 技术的
    • 合法的
    • 环境

第六章 动物抗生素市场分类

  • Aminoglycosides
    • Amikacin
    • 安普霉素
    • 庆大霉素
    • 卡那霉素
    • 新霉素
  • 酰胺醇
    • 迭氮酯
    • 氯霉素
    • 氟苯尼考
    • 甲硫霉素
    • 甲砜霉素
  • 头孢菌素
    • 头孢氨芐
    • 头孢洛尼
    • Cefazolin
    • 头孢维星
    • 头孢噻呋
    • 头孢曲松
  • Fluoroquinolones
    • Ciprofloxacin
    • 达诺沙星
    • 二氟沙星
    • 恩诺沙星
    • 诺氟沙星
    • 奥比沙星
  • 大环内酯类
    • 阿奇霉素
    • 克拉霉素
    • 红霉素
    • 加米霉素
    • 螺旋霉素
    • 替米考星
    • 泰拉霉素
    • 泰乐菌素
  • 其他奎诺酮
    • 西诺沙星
    • 萘啶酸
    • 奥索利酸
    • 吡哌酸
    • 罗索沙星
  • 青霉素
    • 阿莫西林
    • Ampicillin
    • 氯唑西林
    • 苯唑西林
    • 青霉素G
    • 青霉素V
  • 多粘菌素
    • 粘菌素/多粘菌素 E
    • 多粘菌素B
  • 磺胺类药物
    • 磺胺嘧啶
    • 磺胺甲基嘧啶
    • 磺胺甲二唑
    • 磺胺甲噁唑
    • 柳氮磺吡啶
  • 四环霉素
    • 四环霉素
    • 强力霉素
    • 四环霉素
    • 四环霉素
  • 甲氧芐啶
    • 甲氧芐啶 + 磺胺二甲嘧啶
    • 甲氧芐啶-磺胺嘧啶
    • 甲氧芐啶磺胺二甲嘧啶
    • 甲氧芐啶磺胺多辛
    • 甲氧芐啶-磺胺甲噁唑 (TMP-SMX)

7. 动物抗生素市场（依动物类型）

  • 伴同性动物
    • 猫
    • 狗
  • 家畜
    • 牛
    • 家禽
    • 绵羊和山羊
    • 猪

第 8 章动物抗生素市场（依最终用户）

  • 动物生产设施
  • 家中养宠物的人
  • 兽医诊所

9. 动物抗生素市场（依治疗领域）

  • 皮肤感染疾病
  • 胃肠道感染疾病
  • 生殖道感染疾病
  • 呼吸道感染疾病
  • 软组织与伤口感染疾病
  • 全身感染疾病
  • 尿道感染

10. 美洲动物抗生素市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

11. 亚太地区动物抗生素市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

12. 欧洲、中东和非洲动物抗生素市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章 竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023 年
  • 竞争情境分析
  • 战略分析与建议

公司列表

  • Ashish Life Science Private Limited
  • Bimeda Inc.
  • Biogenesis Bago SA
  • CH Boehringer Sohn AG & Co. KG
  • Ceva Sante Animale
  • Dechra Pharmaceuticals PLC
  • Eco Animal Health Group PLC
  • Elanco Animal Health Incorporated
  • Intas Pharmaceuticals Ltd.
  • Krka, dd, Novo mesto
  • Kyoritsuseiyaku Corporation
  • LABORATORIO AVI-MEX
  • LABORATORIOS CALIER, SA
  • Merck KGaA
  • Neogen Corporation
  • Ourofino Group
  • Sequent Scientific Ltd.
  • Vetoquinol SA
  • Virbac SA
  • Zoetis Inc.
Product Code: MRR-1B650A78937F

The Veterinary Antibiotics Market was valued at USD 2.58 billion in 2023 and is projected to grow to USD 2.81 billion in 2024, with a CAGR of 9.01%, reaching USD 4.73 billion by 2030.

KEY MARKET STATISTICS
Base Year [2023] USD 2.58 billion
Estimated Year [2024] USD 2.81 billion
Forecast Year [2030] USD 4.73 billion
CAGR (%) 9.01%

Veterinary antibiotics continue to reshape the landscape of animal health management and treatment, playing a critical role in safeguarding both animal and human populations. The executive summary presents an in-depth analysis of the current state and evolving trends in the veterinary antibiotics market, addressing challenges and opportunities created by emerging antibiotic resistance, regulatory pressures, and evolving market dynamics. This analysis underscores the importance of rigorous research and targeted research methodologies to capture the intricacies of an industry undergoing rapid transformation. In today's highly competitive global environment, stakeholders-from pharmaceutical developers to veterinary practitioners-are recognizing the necessity of aligning their strategies with detailed, data-driven insights. The purpose of this report is to present a comprehensive overview of the market dynamics while providing actionable insights that support strategic decision-making within a field that continues to expand in both complexity and scope.

Our discussion begins with a reflection on the historical perspective of veterinary antibiotics as a foundation, gradually progressing to an examination of groundbreaking changes and technological innovations that are redefining market expectations. The importance of adhering to high standards of efficacy, safety, and environmental considerations is interwoven throughout the narrative, ensuring that industry leaders are well prepared to address contemporary issues such as regulatory realignment, global supply chain adaptation, and the emerging need for antibiotic stewardship. By laying the groundwork with a robust introduction, we set the stage for a deep dive into a market that is both highly dynamic and essential to modern animal health care.

Transformative Shifts in the Veterinary Antibiotics Landscape

In recent years, the veterinary antibiotics market has experienced transformative shifts that are fundamentally altering the way professionals address both longstanding and emergent challenges. Technological innovations, regulatory changes, and evolving market dynamics have converged to drive the development of more targeted and efficient antibiotic therapies.

One of the most significant shifts in the landscape is the transition toward precision veterinary medicine. With advances in diagnostic technologies and genetic profiling, there is a growing ability to tailor antibiotic treatments to specific bacterial pathogens and infections. This precision approach not only improves treatment outcomes but also plays a pivotal role in reducing the emergence of resistance from widespread or empirical antibiotic use.

Changing regulatory frameworks have also played an essential role in catalyzing market transformations. Increased scrutiny regarding the use of antibiotics in animal agriculture, combined with stringent safety protocols, has led to the development of new guidelines that emphasize responsible usage. These evolving regulations are prompting industry stakeholders to adapt quickly, investing in research and development to create novel formulations that comply with higher standards while maintaining therapeutic efficacy.

Additionally, market dynamics are being influenced by heightened consumer awareness and an increased emphasis on the health of companion animals. As pet owners become more conscientious about the treatments administered to their beloved animals, pharmaceutical companies have initiated programs to educate and train veterinary professionals, ensuring that antibiotic prescription practices are aligned with contemporary research findings and responsible medication protocols.

This stage of transformation is complemented by robust efforts in sustainability, particularly the development of innovations aimed at reducing environmental residues and limiting ecological impacts. The combined effects of enhanced diagnostic techniques, more comprehensive regulations, and growing consumer awareness are driving a market that increasingly prioritizes precision, safety, and sustainable practices, ensuring that the use of veterinary antibiotics is both scientifically grounded and ethically managed.

Key Segmentation Insights into Class, Animal Type, End-User, and Therapeutic Areas

A detailed segmentation of the veterinary antibiotics market provides a multi-dimensional understanding of the industry, unveiling intricate patterns and opportunities for growth. The market has been categorized from multiple perspectives, such as the class of antibiotics, the type of animal receiving treatment, the end-user setting, and the therapeutic areas that outline the range of infections treated. By examining the market based on these diverse segmentation criteria, one can identify trends that allow for more targeted and effective strategic decisions.

When considering the classification of antibiotics, it is evident that a variety of drug classes such as Aminoglycosides, Amphenicols, Cephalosporins, Fluoroquinolones, Macrolides, Other Quinolones, Penicillins, Polymixins, Sulfonamides, Tetracyclines, and Trimethoprim have been studied comprehensively. These classes are further subdivided for granular analysis, with Aminoglycosides including drugs such as Amikacin, Apramycin, Gentamicin, Kanamycin, and Neomycin, each offering unique characteristics for treating resistant infections. Similarly, Amphenicols are further delineated to include compounds like Azidamfenicol, Chloramphenicol, Florfenicol, Metiamycin, and Thiamphenicol. In the same manner, the Cephalosporins group is broken down to explore the specific market niches of Cefalexin, Cefalonium, Cefazolin, Cefovecin, Ceftiofur, and Ceftriaxone, enabling a more focused approach when addressing bacterial resistance. With Fluoroquinolones, research encompasses Ciprofloxacin, Danofloxacin, Difloxacin, Enrofloxacin, Norfloxacin, and Orbifloxacin, while Macrolides such as Azithromycin, Clarithromycin, Erythromycin, Gamithromycin, Spiramycin, Tilmicosin, Tulathromycin, and Tylosin are analyzed in parallel. Similarly, the portfolio of Other Quinolones-which includes Cinoxacin, Nalidixic Acid, Oxolinic Acid, Pipemidic Acid, and Rosoxacin-is scrutinized to better understand its market potential. The division of Penicillins into sub-categories featuring Amoxicillin, Ampicillin, Cloxacillin, Oxacillin, Penicillin G, and Penicillin V enables focused insights that drive product differentiation. Moreover, the Polymixins segment is further demarcated into Colistin/Polymyxin E and Polymyxin B, while the Sulfonamides class is detailed by studying Sulfadiazine, Sulfamerazine, Sulfamethizole, Sulfamethoxazole, and Sulfasalazine. The Tetracyclines are analyzed across variations such as Chlortetracycline, Doxycycline, Oxytetracycline, and Tetracycline, and the Trimethoprim class is segmented to explore combinations like Trimethoprim Plus Sulfamethazine, Trimethoprim-Sulfadiazine, Trimethoprim-Sulfadimidine, Trimethoprim-Sulfadoxine, and Trimethoprim-Sulfamethoxazole.

Apart from the intricate drug classifications, analyzing the market by animal type reveals unique trends based on the character of the treated animal. The market traditionally divides into two essential segments-Companion Animals and Livestock. Within the sphere of companion animals, treatments are primarily directed toward common household pets, particularly cats and dogs, where therapeutic approaches need to balance efficacy and safety in delicate physiological environments. Conversely, the livestock segment includes a broader array of animals such as cattle, poultry, sheep and goats, and swine. These groups require tailored treatment strategies reflective of changing husbandry practices, species-specific physiology, and the critical importance of ensuring the food chain's safety.

Furthermore, the segmentation based on end-user settings provides insights into the channel dynamics that shape the market ecosystem. The utilization in specialized animal production facilities is driven by the need for scale and efficiency. This is complemented by the consumer-driven usage patterns observed among household pet owners, where a focus on individualized care is paramount. The role of veterinary clinics remains invaluable, as these institutions act as the interface between advanced research and practical, on-ground application, creating a fertile ground for innovative antibiotic therapies.

Finally, the exploration of therapeutic areas within the market underscores the wide range of applications associated with veterinary antibiotics. Assessment covers a series of therapeutic challenges including dermatological infections, gastrointestinal infections, infections of the reproductive system, respiratory infections, soft tissue and wound infections, systemic infections, and urinary tract infections. By correlating these therapeutic areas with the specific needs of different animal segments, stakeholders are enabled to tailor interventions based on both economic and clinical metrics, ensuring that each application area is optimally served through targeted research, timely innovation, and customized treatment protocols.

In summary, segmentation reveals the complex and layered nature of the veterinary antibiotics market. It is this detailed and structured approach that allows for an in-depth understanding of both macro and micro-level trends, laying the foundation for precise market targeting and the identification of latent opportunities within every sub-segment.

Based on Class, market is studied across Aminoglycosides, Amphenicols, Cephalosporins, Fluoroquinolones, Macrolides, Other Quinolones, Penicillins, Polymixins, Sulfonamides, Tetracyclines, and Trimethoprim. The Aminoglycosides is further studied across Amikacin, Apramycin, Gentamicin, Kanamycin, and Neomycin. The Amphenicols is further studied across Azidamfenicol, Chloramphenicol, Florfenicol, Metiamycin, and Thiamphenicol. The Cephalosporins is further studied across Cefalexin, Cefalonium, Cefazolin, Cefovecin, Ceftiofur, and Ceftriaxone. The Fluoroquinolones is further studied across Ciprofloxacin, Danofloxacin, Difloxacin, Enrofloxacin, Norfloxacin, and Orbifloxacin. The Macrolides is further studied across Azithromycin, Clarithromycin, Erythromycin, Gamithromycin, Spiramycin, Tilmicosin, Tulathromycin, and Tylosin. The Other Quinolones is further studied across Cinoxacin, Nalidixic Acid, Oxolinic Acid, Pipemidic Acid, and Rosoxacin. The Penicillins is further studied across Amoxicillin, Ampicillin, Cloxacillin, Oxacillin, Penicillin G, and Penicillin V. The Polymixins is further studied across Colistin/Polymyxin E and Polymyxin B. The Sulfonamides is further studied across Sulfadiazine, Sulfamerazine, Sulfamethizole, Sulfamethoxazole, and Sulfasalazine. The Tetracyclines is further studied across Chlortetracycline, Doxycycline, Oxytetracycline, and Tetracycline. The Trimethoprim is further studied across Trimethoprim Plus Sulfamethazine, Trimethoprim-Sulfadiazine, Trimethoprim-Sulfadimidine, Trimethoprim-Sulfadoxine, and Trimethoprim-Sulfamethoxazole (TMP-SMX).

Based on Animal Type, market is studied across Companion Animals and Livestock. The Companion Animals is further studied across Cats and Dogs. The Livestock is further studied across Cattle, Poultry, Sheep & Goats, and Swine.

Based on End-User, market is studied across Animal Production Facilities, Household Pet Owners, and Veterinary Clinics.

Based on Therapeutic Areas, market is studied across Dermatological Infections, Gastrointestinal Infections, Reproductive System Infections, Respiratory Infections, Soft Tissue & Wound Infections, Systemic Infections, and Urinary Tract Infections.

Analyzing Key Regional Insights Across Global Markets

A meticulous examination of the geographic landscape illustrates significant regional disparities and growth drivers that influence the global veterinary antibiotics market. The distinct markets in the Americas, Europe, Middle East & Africa, and Asia-Pacific each present unique characteristics that not only reflect local economic and regulatory conditions but also denote significant potential for strategic expansion and investment.

In the Americas, market dynamics have been marked by a swift adaptation to evolving regulatory frameworks and heightened consumer awareness regarding animal welfare and public health. These factors have spurred market growth, supported by high adoption rates of precision treatments and modern therapeutic approaches in both companion animal and livestock sectors. Regional economic stability and an increasing focus on innovation have bolstered research and development initiatives, enabling breakthroughs in treatment efficacy and safety.

Europe, along with the Middle East & Africa, exhibits a complex interplay of regulatory restrictions and collaborative research. European markets in particular benefit from a highly regulated environment, necessitating strict compliance and comprehensive stewardship measures that influence product development pipelines. The focus on sustainability and environmental protection further encourages the development of antibiotics with reduced ecological footprints. In the Middle East & Africa, market growth is driven by a rising demand for improved animal health protocols as emerging economies invest in modernizing their agricultural practices and veterinary care systems. These regions are witnessing increasing governmental support for enhanced veterinary services, indirectly fostering expansions in the availability and diversity of antibiotic treatments.

The Asia-Pacific market is distinguished by dynamic economic growth and rapid urbanization that are reshaping livestock practices and pet ownership trends. Increased disposable incomes, accelerated technological adoption, and expanding consumer bases in emerging countries contribute to the heightened demand for state-of-the-art veterinary care. The region's market is characterized by high-volume production of veterinary antibiotics tailored to meet diverse requirements across both extensive livestock operations and the evolving pet care segment. Additionally, the Asia-Pacific markets frequently benefit from proactive public and private partnerships which drive investments into research, manufacturing efficiency, and the integration of global best practices in veterinary medicine.

Altogether, the divergence and distinctiveness of regional markets underscore the importance of localized strategies that consider cultural, economic, and regulatory factors. A deep understanding of these geographical nuances enables stakeholders to harness growth opportunities tailored to specific markets while maintaining a cohesive global strategy that leverages innovation and sustainability.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, Massachusetts, New York, North Carolina, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Profile of Leading Companies Driving Growth and Innovation

The competitive landscape of the veterinary antibiotics market is spearheaded by a dynamic cohort of companies, each contributing to the sector's innovation and market expansion. In this environment, organizations such as Ashish Life Science Private Limited, Bimeda Inc., and Biogenesis Bago S.A. have differentiated themselves through rigorous research and a steadfast commitment to high-quality product portfolios. These companies have become known for integrating cutting-edge technologies into their production processes, resulting in therapies that are both effective and safe.

Other industry leaders, including C.H. Boehringer Sohn AG & Co. KG and Ceva Sante Animale, have built strong reputations by leveraging deep expertise in both human and veterinary pharmaceuticals. They maintain strategic collaborations with research institutions, enabling them to keep pace with the rapidly evolving scientific environment and ensure that their product offerings are based on the latest clinical evidence. Dechra Pharmaceuticals PLC, Eco Animal Health Group PLC, and Elanco Animal Health Incorporated also play critical roles, driving market growth through focused investment in research and an unyielding commitment to meeting modern regulatory standards.

Intas Pharmaceuticals Ltd., along with established entities such as Krka, d. d., Novo mesto, continues to expand their presence by capitalizing on innovation and diversification of product pipelines. Kyoritsuseiyaku Corporation and LABORATORIO AVI-MEX represent robust contributors in this competitive landscape, underscoring the ever-more global reach of the industry. LABORATORIOS CALIER, S.A., Merck KGaA, Neogen Corporation, and Ourofino Group have all demonstrated a capacity to adapt to shifting market demands through agile business strategies and the consistent delivery of high-performance therapies. Moreover, companies like Sequent Scientific Ltd., Vetoquinol SA, Virbac SA, and Zoetis Inc. have reinforced their market positions through strategic acquisitions, expansive research initiatives, and a deep-rooted dedication to advancing animal health. Their comprehensive and specialized portfolios enable them to meet a diverse range of veterinary needs while staying competitive amid evolving industry trends.

The robust profile of these key companies reflects an unwavering commitment to innovation, quality, and customer-centric solutions. By continuously investing in research and embracing strategic mergers and alliances, these leading players are not only bolstering their market shares but also contributing to significant advancements that are shaping the future of veterinary medicine. Their efforts are driving improvements in both therapeutic efficacy and sustainable practices, ensuring that animal health remains at the forefront of the global veterinary antibiotics market.

The report delves into recent significant developments in the Veterinary Antibiotics Market, highlighting leading vendors and their innovative profiles. These include Ashish Life Science Private Limited, Bimeda Inc., Biogenesis Bago S.A., C.H. Boehringer Sohn AG & Co. KG, Ceva Sante Animale, Dechra Pharmaceuticals PLC, Eco Animal Health Group PLC, Elanco Animal Health Incorporated, Intas Pharmaceuticals Ltd., Krka, d. d., Novo mesto, Kyoritsuseiyaku Corporation, LABORATORIO AVI-MEX, LABORATORIOS CALIER, S.A., Merck KGaA, Neogen Corporation, Ourofino Group, Sequent Scientific Ltd., Vetoquinol SA, Virbac SA, and Zoetis Inc.. Actionable Recommendations to Enhance Market Positioning and Growth

For industry leaders seeking to capitalize on emerging trends and reinforce their market positioning, several actionable recommendations can be drawn from the current analysis. Foremost, a sustained commitment to research and development is essential. Leaders should invest in innovative diagnostic technologies and precision medicine approaches, thereby enabling the creation of targeted antibiotic therapies that not only improve treatment outcomes but also address concerns related to antimicrobial resistance.

It is equally important for decision-makers to prioritize regulatory compliance and proactive engagement with evolving legislation. By maintaining close collaboration with regulatory bodies and ensuring that product development strategies are aligned with globally recognized standards, companies can safeguard their market presence and avert potential setbacks related to non-compliance.

In addition, market expansion strategies should be driven by a granular understanding of regional dynamics. Firms need to tailor their approaches based on detailed insights into the Americas, Europe, Middle East & Africa, and Asia-Pacific regions. This localized strategy will enable companies to optimize resource allocation, adapt product formulations to meet specific regional requirements, and leverage partnerships with local stakeholders to enhance distribution networks.

Another key consideration is the embrace of digital transformation. Investing in advanced analytics and artificial intelligence can provide real-time insights into market trends, customer behavior, and competitive activity. A data-driven approach not only enhances decision-making processes but also ensures agile responses to rapid market changes. Furthermore, companies would benefit by expanding collaborations with research institutions and industry experts to foster innovation and develop sustainable practices that lessen environmental impact.

Finally, organizations must adopt a customer-centric model that emphasizes tailored solutions in both companion animal and livestock segments. This approach requires continuous engagement with veterinary practitioners, training initiatives for end users, and comprehensive support systems that ensure the successful implementation of new therapies. By integrating these strategies, industry leaders can solidify their competitive edge, drive sustainable growth, and contribute positively to the broader narrative of veterinary healthcare innovation.

Concluding Reflections on the Veterinary Antibiotics Market

The comprehensive analysis underscores the intricate dynamics underpinning the current and future state of the veterinary antibiotics market. This exploration has traversed a spectrum of key dimensions, from transformative innovations and nuanced segmentation insights to region-specific trends and the strategic moves of industry titans. At every level, the narrative reveals a market that is not only vast in its complexity but also rich with opportunities for investment, growth, and sustainable development.

A critical takeaway from this review is the importance of balancing rapid technological advancements with steadfast commitments to safety, regulatory compliance, and environmental considerations. The sector's evolution is being driven by a robust demand for precision in animal health interventions, alongside an urgent need to mitigate issues related to antimicrobial resistance. As veterinary professionals and industry stakeholders capitalize on these trends, it becomes evident that success will depend on an adaptive approach that embraces both local nuances and global best practices.

The integrated insights presented herein serve not only as a reflection of the market condition but also as a roadmap for future strategic directions. The interplay between scientific innovation, regulatory evolution, and market expansion creates a fertile ground for further breakthroughs, ultimately driving enhanced health outcomes for animals across various segments. Reflecting on these factors, it is clear that the veterinary antibiotics market is poised to offer substantial rewards for those who navigate its challenges with foresight and strategic agility.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing livestock population with increasing demand for dairy and meat products
      • 5.1.1.2. Rising prevalence of zoonotic diseases and other infections in animals
      • 5.1.1.3. Increasing companionship and humanization of pets across the globe
    • 5.1.2. Restraints
      • 5.1.2.1. Growing concerns about antibiotic resistance in veterinary disease antigens
    • 5.1.3. Opportunities
      • 5.1.3.1. Advances in drug delivery systems that enhance the efficacy and safety of veterinary antibiotics
      • 5.1.3.2. Growing potential with the development of new antibiotics with novel mechanisms
    • 5.1.4. Challenges
      • 5.1.4.1. Issues related to the ban and restricted use of veterinary antibiotics in different regions
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Class: Rising demand for amphenicols in various countries for treating respiratory diseases in cattle and fish
    • 5.2.2. Animal Type: Usage of veterinary-antibiotics livestocks to ensure safe food supply chains and economic stability for farmers
    • 5.2.3. End-User: Adoption of veterinary antibiotics in animal production facilities to prevent disease outbreaks and ensure optimal growth rates.
    • 5.2.4. Therapeutic Areas: Utilization of veterinary antibiotics in respiratory infection to prevent outbreaks and maintain herd health,
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Veterinary Antibiotics Market, by Class

  • 6.1. Introduction
  • 6.2. Aminoglycosides
    • 6.2.1. Amikacin
    • 6.2.2. Apramycin
    • 6.2.3. Gentamicin
    • 6.2.4. Kanamycin
    • 6.2.5. Neomycin
  • 6.3. Amphenicols
    • 6.3.1. Azidamfenicol
    • 6.3.2. Chloramphenicol
    • 6.3.3. Florfenicol
    • 6.3.4. Metiamycin
    • 6.3.5. Thiamphenicol
  • 6.4. Cephalosporins
    • 6.4.1. Cefalexin
    • 6.4.2. Cefalonium
    • 6.4.3. Cefazolin
    • 6.4.4. Cefovecin
    • 6.4.5. Ceftiofur
    • 6.4.6. Ceftriaxone
  • 6.5. Fluoroquinolones
    • 6.5.1. Ciprofloxacin
    • 6.5.2. Danofloxacin
    • 6.5.3. Difloxacin
    • 6.5.4. Enrofloxacin
    • 6.5.5. Norfloxacin
    • 6.5.6. Orbifloxacin
  • 6.6. Macrolides
    • 6.6.1. Azithromycin
    • 6.6.2. Clarithromycin
    • 6.6.3. Erythromycin
    • 6.6.4. Gamithromycin
    • 6.6.5. Spiramycin
    • 6.6.6. Tilmicosin
    • 6.6.7. Tulathromycin
    • 6.6.8. Tylosin
  • 6.7. Other Quinolones
    • 6.7.1. Cinoxacin
    • 6.7.2. Nalidixic Acid
    • 6.7.3. Oxolinic Acid
    • 6.7.4. Pipemidic Acid
    • 6.7.5. Rosoxacin
  • 6.8. Penicillins
    • 6.8.1. Amoxicillin
    • 6.8.2. Ampicillin
    • 6.8.3. Cloxacillin
    • 6.8.4. Oxacillin
    • 6.8.5. Penicillin G
    • 6.8.6. Penicillin V
  • 6.9. Polymixins
    • 6.9.1. Colistin/Polymyxin E
    • 6.9.2. Polymyxin B
  • 6.10. Sulfonamides
    • 6.10.1. Sulfadiazine
    • 6.10.2. Sulfamerazine
    • 6.10.3. Sulfamethizole
    • 6.10.4. Sulfamethoxazole
    • 6.10.5. Sulfasalazine
  • 6.11. Tetracyclines
    • 6.11.1. Chlortetracycline
    • 6.11.2. Doxycycline
    • 6.11.3. Oxytetracycline
    • 6.11.4. Tetracycline
  • 6.12. Trimethoprim
    • 6.12.1. Trimethoprim Plus Sulfamethazine
    • 6.12.2. Trimethoprim-Sulfadiazine
    • 6.12.3. Trimethoprim-Sulfadimidine
    • 6.12.4. Trimethoprim-Sulfadoxine
    • 6.12.5. Trimethoprim-Sulfamethoxazole (TMP-SMX)

7. Veterinary Antibiotics Market, by Animal Type

  • 7.1. Introduction
  • 7.2. Companion Animals
    • 7.2.1. Cats
    • 7.2.2. Dogs
  • 7.3. Livestock
    • 7.3.1. Cattle
    • 7.3.2. Poultry
    • 7.3.3. Sheep & Goats
    • 7.3.4. Swine

8. Veterinary Antibiotics Market, by End-User

  • 8.1. Introduction
  • 8.2. Animal Production Facilities
  • 8.3. Household Pet Owners
  • 8.4. Veterinary Clinics

9. Veterinary Antibiotics Market, by Therapeutic Areas

  • 9.1. Introduction
  • 9.2. Dermatological Infections
  • 9.3. Gastrointestinal Infections
  • 9.4. Reproductive System Infections
  • 9.5. Respiratory Infections
  • 9.6. Soft Tissue & Wound Infections
  • 9.7. Systemic Infections
  • 9.8. Urinary Tract Infections

10. Americas Veterinary Antibiotics Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Veterinary Antibiotics Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Veterinary Antibiotics Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Innovative Vetlen pouch enhances antibiotic delivery for veterinary care
    • 13.3.2. Innovative antibacterial agents target antibiotic-resistant infections
    • 13.3.3. FDA establishes veterinary innovation centers to advance animal health
    • 13.3.4. Purdue and Akston Biosciences partner for innovative canine cancer treatment development
    • 13.3.5. Dechra Pharmaceuticals to acquire invetx for enhanced veterinary biotherapeutics portfolio
    • 13.3.6. FDA approves pradalex for targeted Use in cattle and swine respiratory treatment
    • 13.3.7. Blacksmith Medicines and Zoetis collaborate to tackle antibiotic resistance in animal health
  • 13.4. Strategy Analysis & Recommendation
    • 13.4.1. Intas Pharmaceuticals Ltd.
    • 13.4.2. Merck KGaA
    • 13.4.3. Elanco Animal Health Incorporated
    • 13.4.4. Zoetis Inc.

Companies Mentioned

  • 1. Ashish Life Science Private Limited
  • 2. Bimeda Inc.
  • 3. Biogenesis Bago S.A.
  • 4. C.H. Boehringer Sohn AG & Co. KG
  • 5. Ceva Sante Animale
  • 6. Dechra Pharmaceuticals PLC
  • 7. Eco Animal Health Group PLC
  • 8. Elanco Animal Health Incorporated
  • 9. Intas Pharmaceuticals Ltd.
  • 10. Krka, d. d., Novo mesto
  • 11. Kyoritsuseiyaku Corporation
  • 12. LABORATORIO AVI-MEX
  • 13. LABORATORIOS CALIER, S.A.
  • 14. Merck KGaA
  • 15. Neogen Corporation
  • 16. Ourofino Group
  • 17. Sequent Scientific Ltd.
  • 18. Vetoquinol SA
  • 19. Virbac SA
  • 20. Zoetis Inc.

LIST OF FIGURES

  • FIGURE 1. VETERINARY ANTIBIOTICS MARKET MULTI-CURRENCY
  • FIGURE 2. VETERINARY ANTIBIOTICS MARKET MULTI-LANGUAGE
  • FIGURE 3. VETERINARY ANTIBIOTICS MARKET RESEARCH PROCESS
  • FIGURE 4. VETERINARY ANTIBIOTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 5. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, 2018-2030 (USD THOUSAND)
  • FIGURE 6. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD THOUSAND)
  • FIGURE 7. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD THOUSAND)
  • FIGURE 8. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CLASS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CLASS, 2023 VS 2024 VS 2030 (USD THOUSAND)
  • FIGURE 10. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY ANIMAL TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY ANIMAL TYPE, 2023 VS 2024 VS 2030 (USD THOUSAND)
  • FIGURE 12. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD THOUSAND)
  • FIGURE 14. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2023 VS 2024 VS 2030 (USD THOUSAND)
  • FIGURE 16. AMERICAS VETERINARY ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS VETERINARY ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD THOUSAND)
  • FIGURE 18. UNITED STATES VETERINARY ANTIBIOTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES VETERINARY ANTIBIOTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD THOUSAND)
  • FIGURE 20. ASIA-PACIFIC VETERINARY ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC VETERINARY ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD THOUSAND)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA VETERINARY ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA VETERINARY ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD THOUSAND)
  • FIGURE 24. VETERINARY ANTIBIOTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. VETERINARY ANTIBIOTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. VETERINARY ANTIBIOTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, 2018-2030 (USD THOUSAND)
  • TABLE 4. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 5. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 6. VETERINARY ANTIBIOTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CLASS, 2018-2030 (USD THOUSAND)
  • TABLE 8. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY AMINOGLYCOSIDES, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 9. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY AMIKACIN, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 10. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY APRAMYCIN, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 11. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY GENTAMICIN, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 12. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY KANAMYCIN, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 13. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY NEOMYCIN, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 14. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2030 (USD THOUSAND)
  • TABLE 15. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY AMPHENICOLS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 16. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY AZIDAMFENICOL, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 17. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CHLORAMPHENICOL, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 18. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY FLORFENICOL, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 19. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY METIAMYCIN, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 20. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY THIAMPHENICOL, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 21. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY AMPHENICOLS, 2018-2030 (USD THOUSAND)
  • TABLE 22. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORINS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 23. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CEFALEXIN, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 24. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CEFALONIUM, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 25. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CEFAZOLIN, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 26. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CEFOVECIN, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 27. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CEFTIOFUR, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 28. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CEFTRIAXONE, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 29. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORINS, 2018-2030 (USD THOUSAND)
  • TABLE 30. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY FLUOROQUINOLONES, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 31. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CIPROFLOXACIN, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 32. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY DANOFLOXACIN, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 33. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY DIFLOXACIN, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 34. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY ENROFLOXACIN, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 35. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY NORFLOXACIN, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 36. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY ORBIFLOXACIN, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 37. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY FLUOROQUINOLONES, 2018-2030 (USD THOUSAND)
  • TABLE 38. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY MACROLIDES, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 39. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY AZITHROMYCIN, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 40. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CLARITHROMYCIN, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 41. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY ERYTHROMYCIN, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 42. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY GAMITHROMYCIN, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 43. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SPIRAMYCIN, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 44. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TILMICOSIN, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 45. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TULATHROMYCIN, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 46. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TYLOSIN, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 47. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY MACROLIDES, 2018-2030 (USD THOUSAND)
  • TABLE 48. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY OTHER QUINOLONES, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 49. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CINOXACIN, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 50. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY NALIDIXIC ACID, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 51. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY OXOLINIC ACID, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 52. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY PIPEMIDIC ACID, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 53. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY ROSOXACIN, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 54. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY OTHER QUINOLONES, 2018-2030 (USD THOUSAND)
  • TABLE 55. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY PENICILLINS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 56. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY AMOXICILLIN, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 57. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY AMPICILLIN, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 58. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CLOXACILLIN, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 59. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY OXACILLIN, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 60. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY PENICILLIN G, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 61. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY PENICILLIN V, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 62. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY PENICILLINS, 2018-2030 (USD THOUSAND)
  • TABLE 63. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY POLYMIXINS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 64. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY COLISTIN/POLYMYXIN E, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 65. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY POLYMYXIN B, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 66. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY POLYMIXINS, 2018-2030 (USD THOUSAND)
  • TABLE 67. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SULFONAMIDES, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 68. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SULFADIAZINE, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 69. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SULFAMERAZINE, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 70. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SULFAMETHIZOLE, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 71. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SULFAMETHOXAZOLE, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 72. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SULFASALAZINE, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 73. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SULFONAMIDES, 2018-2030 (USD THOUSAND)
  • TABLE 74. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TETRACYCLINES, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 75. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CHLORTETRACYCLINE, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 76. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY DOXYCYCLINE, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 77. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY OXYTETRACYCLINE, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 78. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TETRACYCLINE, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 79. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TETRACYCLINES, 2018-2030 (USD THOUSAND)
  • TABLE 80. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TRIMETHOPRIM, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 81. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TRIMETHOPRIM PLUS SULFAMETHAZINE, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 82. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TRIMETHOPRIM-SULFADIAZINE, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 83. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TRIMETHOPRIM-SULFADIMIDINE, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 84. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TRIMETHOPRIM-SULFADOXINE, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 85. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TRIMETHOPRIM-SULFAMETHOXAZOLE (TMP-SMX), BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 86. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TRIMETHOPRIM, 2018-2030 (USD THOUSAND)
  • TABLE 87. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 88. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY COMPANION ANIMALS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 89. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CATS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 90. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY DOGS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 91. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD THOUSAND)
  • TABLE 92. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY LIVESTOCK, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 93. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CATTLE, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 94. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY POULTRY, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 95. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SHEEP & GOATS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 96. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SWINE, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 97. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY LIVESTOCK, 2018-2030 (USD THOUSAND)
  • TABLE 98. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
  • TABLE 99. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY ANIMAL PRODUCTION FACILITIES, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 100. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY HOUSEHOLD PET OWNERS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 101. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 102. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD THOUSAND)
  • TABLE 103. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY DERMATOLOGICAL INFECTIONS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 104. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 105. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY REPRODUCTIVE SYSTEM INFECTIONS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 106. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY RESPIRATORY INFECTIONS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 107. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SOFT TISSUE & WOUND INFECTIONS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 108. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SYSTEMIC INFECTIONS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 109. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY URINARY TRACT INFECTIONS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 110. AMERICAS VETERINARY ANTIBIOTICS MARKET SIZE, BY CLASS, 2018-2030 (USD THOUSAND)
  • TABLE 111. AMERICAS VETERINARY ANTIBIOTICS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2030 (USD THOUSAND)
  • TABLE 112. AMERICAS VETERINARY ANTIBIOTICS MARKET SIZE, BY AMPHENICOLS, 2018-2030 (USD THOUSAND)
  • TABLE 113. AMERICAS VETERINARY ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORINS, 2018-2030 (USD THOUSAND)
  • TABLE 114. AMERICAS VETERINARY ANTIBIOTICS MARKET SIZE, BY FLUOROQUINOLONES, 2018-2030 (USD THOUSAND)
  • TABLE 115. AMERICAS VETERINARY ANTIBIOTICS MARKET SIZE, BY MACROLIDES, 2018-2030 (USD THOUSAND)
  • TABLE 116. AMERICAS VETERINARY ANTIBIOTICS MARKET SIZE, BY OTHER QUINOLONES, 2018-2030 (USD THOUSAND)
  • TABLE 117. AMERICAS VETERINARY ANTIBIOTICS MARKET SIZE, BY PENICILLINS, 2018-2030 (USD THOUSAND)
  • TABLE 118. AMERICAS VETERINARY ANTIBIOTICS MARKET SIZE, BY POLYMIXINS, 2018-2030 (USD THOUSAND)
  • TABLE 119. AMERICAS VETERINARY ANTIBIOTICS MARKET SIZE, BY SULFONAMIDES, 2018-2030 (USD THOUSAND)
  • TABLE 120. AMERICAS VETERINARY ANTIBIOTICS MARKET SIZE, BY TETRACYCLINES, 2018-2030 (USD THOUSAND)
  • TABLE 121. AMERICAS VETERINARY ANTIBIOTICS MARKET SIZE, BY TRIMETHOPRIM, 2018-2030 (USD THOUSAND)
  • TABLE 122. AMERICAS VETERINARY ANTIBIOTICS MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 123. AMERICAS VETERINARY ANTIBIOTICS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD THOUSAND)
  • TABLE 124. AMERICAS VETERINARY ANTIBIOTICS MARKET SIZE, BY LIVESTOCK, 2018-2030 (USD THOUSAND)
  • TABLE 125. AMERICAS VETERINARY ANTIBIOTICS MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
  • TABLE 126. AMERICAS VETERINARY ANTIBIOTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD THOUSAND)
  • TABLE 127. AMERICAS VETERINARY ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 128. ARGENTINA VETERINARY ANTIBIOTICS MARKET SIZE, BY CLASS, 2018-2030 (USD THOUSAND)
  • TABLE 129. ARGENTINA VETERINARY ANTIBIOTICS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2030 (USD THOUSAND)
  • TABLE 130. ARGENTINA VETERINARY ANTIBIOTICS MARKET SIZE, BY AMPHENICOLS, 2018-2030 (USD THOUSAND)
  • TABLE 131. ARGENTINA VETERINARY ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORINS, 2018-2030 (USD THOUSAND)
  • TABLE 132. ARGENTINA VETERINARY ANTIBIOTICS MARKET SIZE, BY FLUOROQUINOLONES, 2018-2030 (USD THOUSAND)
  • TABLE 133. ARGENTINA VETERINARY ANTIBIOTICS MARKET SIZE, BY MACROLIDES, 2018-2030 (USD THOUSAND)
  • TABLE 134. ARGENTINA VETERINARY ANTIBIOTICS MARKET SIZE, BY OTHER QUINOLONES, 2018-2030 (USD THOUSAND)
  • TABLE 135. ARGENTINA VETERINARY ANTIBIOTICS MARKET SIZE, BY PENICILLINS, 2018-2030 (USD THOUSAND)
  • TABLE 136. ARGENTINA VETERINARY ANTIBIOTICS MARKET SIZE, BY POLYMIXINS, 2018-2030 (USD THOUSAND)
  • TABLE 137. ARGENTINA VETERINARY ANTIBIOTICS MARKET SIZE, BY SULFONAMIDES, 2018-2030 (USD THOUSAND)
  • TABLE 138. ARGENTINA VETERINARY ANTIBIOTICS MARKET SIZE, BY TETRACYCLINES, 2018-2030 (USD THOUSAND)
  • TABLE 139. ARGENTINA VETERINARY ANTIBIOTICS MARKET SIZE, BY TRIMETHOPRIM, 2018-2030 (USD THOUSAND)
  • TABLE 140. ARGENTINA VETERINARY ANTIBIOTICS MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 141. ARGENTINA VETERINARY ANTIBIOTICS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD THOUSAND)
  • TABLE 142. ARGENTINA VETERINARY ANTIBIOTICS MARKET SIZE, BY LIVESTOCK, 2018-2030 (USD THOUSAND)
  • TABLE 143. ARGENTINA VETERINARY ANTIBIOTICS MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
  • TABLE 144. ARGENTINA VETERINARY ANTIBIOTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD THOUSAND)
  • TABLE 145. BRAZIL VETERINARY ANTIBIOTICS MARKET SIZE, BY CLASS, 2018-2030 (USD THOUSAND)
  • TABLE 146. BRAZIL VETERINARY ANTIBIOTICS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2030 (USD THOUSAND)
  • TABLE 147. BRAZIL VETERINARY ANTIBIOTICS MARKET SIZE, BY AMPHENICOLS, 2018-2030 (USD THOUSAND)
  • TABLE 148. BRAZIL VETERINARY ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORINS, 2018-2030 (USD THOUSAND)
  • TABLE 149. BRAZIL VETERINARY ANTIBIOTICS MARKET SIZE, BY FLUOROQUINOLONES, 2018-2030 (USD THOUSAND)
  • TABLE 150. BRAZIL VETERINARY ANTIBIOTICS MARKET SIZE, BY MACROLIDES, 2018-2030 (USD THOUSAND)
  • TABLE 151. BRAZIL VETERINARY ANTIBIOTICS MARKET SIZE, BY OTHER QUINOLONES, 2018-2030 (USD THOUSAND)
  • TABLE 152. BRAZIL VETERINARY ANTIBIOTICS MARKET SIZE, BY PENICILLINS, 2018-2030 (USD THOUSAND)
  • TABLE 153. BRAZIL VETERINARY ANTIBIOTICS MARKET SIZE, BY POLYMIXINS, 2018-2030 (USD THOUSAND)
  • TABLE 154. BRAZIL VETERINARY ANTIBIOTICS MARKET SIZE, BY SULFONAMIDES, 2018-2030 (USD THOUSAND)
  • TABLE 155. BRAZIL VETERINARY ANTIBIOTICS MARKET SIZE, BY TETRACYCLINES, 2018-2030 (USD THOUSAND)
  • TABLE 156. BRAZIL VETERINARY ANTIBIOTICS MARKET SIZE, BY TRIMETHOPRIM, 2018-2030 (USD THOUSAND)
  • TABLE 157. BRAZIL VETERINARY ANTIBIOTICS MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 158. BRAZIL VETERINARY ANTIBIOTICS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD THOUSAND)
  • TABLE 159. BRAZIL VETERINARY ANTIBIOTICS MARKET SIZE, BY LIVESTOCK, 2018-2030 (USD THOUSAND)
  • TABLE 160. BRAZIL VETERINARY ANTIBIOTICS MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
  • TABLE 161. BRAZIL VETERINARY ANTIBIOTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD THOUSAND)
  • TABLE 162. CANADA VETERINARY ANTIBIOTICS MARKET SIZE, BY CLASS, 2018-2030 (USD THOUSAND)
  • TABLE 163. CANADA VETERINARY ANTIBIOTICS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2030 (USD THOUSAND)
  • TABLE 164. CANADA VETERINARY ANTIBIOTICS MARKET SIZE, BY AMPHENICOLS, 2018-2030 (USD THOUSAND)
  • TABLE 165. CANADA VETERINARY ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORINS, 2018-2030 (USD THOUSAND)
  • TABLE 166. CANADA VETERINARY ANTIBIOTICS MARKET SIZE, BY FLUOROQUINOLONES, 2018-2030 (USD THOUSAND)
  • TABLE 167. CANADA VETERINARY ANTIBIOTICS MARKET SIZE, BY MACROLIDES, 2018-2030 (USD THOUSAND)
  • TABLE 168. CANADA VETERINARY ANTIBIOTICS MARKET SIZE, BY OTHER QUINOLONES, 2018-2030 (USD THOUSAND)
  • TABLE 169. CANADA VETERINARY ANTIBIOTICS MARKET SIZE, BY PENICILLINS, 2018-2030 (USD THOUSAND)
  • TABLE 170. CANADA VETERINARY ANTIBIOTICS MARKET SIZE, BY POLYMIXINS, 2018-2030 (USD THOUSAND)
  • TABLE 171. CANADA VETERINARY ANTIBIOTICS MARKET SIZE, BY SULFONAMIDES, 2018-2030 (USD THOUSAND)
  • TABLE 172. CANADA VETERINARY ANTIBIOTICS MARKET SIZE, BY TETRACYCLINES, 2018-2030 (USD THOUSAND)
  • TABLE 173. CANADA VETERINARY ANTIBIOTICS MARKET SIZE, BY TRIMETHOPRIM, 2018-2030 (USD THOUSAND)
  • TABLE 174. CANADA VETERINARY ANTIBIOTICS MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 175. CANADA VETERINARY ANTIBIOTICS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD THOUSAND)
  • TABLE 176. CANADA VETERINARY ANTIBIOTICS MARKET SIZE, BY LIVESTOCK, 2018-2030 (USD THOUSAND)
  • TABLE 177. CANADA VETERINARY ANTIBIOTICS MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
  • TABLE 178. CANADA VETERINARY ANTIBIOTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD THOUSAND)
  • TABLE 179. MEXICO VETERINARY ANTIBIOTICS MARKET SIZE, BY CLASS, 2018-2030 (USD THOUSAND)
  • TABLE 180. MEXICO VETERINARY ANTIBIOTICS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2030 (USD THOUSAND)
  • TABLE 181. MEXICO VETERINARY ANTIBIOTICS MARKET SIZE, BY AMPHENICOLS, 2018-2030 (USD THOUSAND)
  • TABLE 182. MEXICO VETERINARY ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORINS, 2018-2030 (USD THOUSAND)
  • TABLE 183. MEXICO VETERINARY ANTIBIOTICS MARKET SIZE, BY FLUOROQUINOLONES, 2018-2030 (USD THOUSAND)
  • TABLE 184. MEXICO VETERINARY ANTIBIOTICS MARKET SIZE, BY MACROLIDES, 2018-2030 (USD THOUSAND)
  • TABLE 185. MEXICO VETERINARY ANTIBIOTICS MARKET SIZE, BY OTHER QUINOLONES, 2018-2030 (USD THOUSAND)
  • TABLE 186. MEXICO VETERINARY ANTIBIOTICS MARKET SIZE, BY PENICILLINS, 2018-2030 (USD THOUSAND)
  • TABLE 187. MEXICO VETERINARY ANTIBIOTICS MARKET SIZE, BY POLYMIXINS, 2018-2030 (USD THOUSAND)
  • TABLE 188. MEXICO VETERINARY ANTIBIOTICS MARKET SIZE, BY SULFONAMIDES, 2018-2030 (USD THOUSAND)
  • TABLE 189. MEXICO VETERINARY ANTIBIOTICS MARKET SIZE, BY TETRACYCLINES, 2018-2030 (USD THOUSAND)
  • TABLE 190. MEXICO VETERINARY ANTIBIOTICS MARKET SIZE, BY TRIMETHOPRIM, 2018-2030 (USD THOUSAND)
  • TABLE 191. MEXICO VETERINARY ANTIBIOTICS MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 192. MEXICO VETERINARY ANTIBIOTICS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD THOUSAND)
  • TABLE 193. MEXICO VETERINARY ANTIBIOTICS MARKET SIZE, BY LIVESTOCK, 2018-2030 (USD THOUSAND)
  • TABLE 194. MEXICO VETERINARY ANTIBIOTICS MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
  • TABLE 195. MEXICO VETERINARY ANTIBIOTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD THOUSAND)
  • TABLE 196. UNITED STATES VETERINARY ANTIBIOTICS MARKET SIZE, BY CLASS, 2018-2030 (USD THOUSAND)
  • TABLE 197. UNITED STATES VETERINARY ANTIBIOTICS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2030 (USD THOUSAND)
  • TABLE 198. UNITED STATES VETERINARY ANTIBIOTICS MARKET SIZE, BY AMPHENICOLS, 2018-2030 (USD THOUSAND)
  • TABLE 199. UNITED STATES VETERINARY ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORINS, 2018-2030 (USD THOUSAND)
  • TABLE 200. UNITED STATES VETERINARY ANTIBIOTICS MARKET SIZE, BY FLUOROQUINOLONES, 2018-2030 (USD THOUSAND)
  • TABLE 201. UNITED STATES VETERINARY ANTIBIOTICS MARKET SIZE, BY MACROLIDES, 2018-2030 (USD THOUSAND)
  • TABLE 202. UNITED STATES VETERINARY ANTIBIOTICS MARKET SIZE, BY OTHER QUINOLONES, 2018-2030 (USD THOUSAND)
  • TABLE 203. UNITED STATES VETERINARY ANTIBIOTICS MARKET SIZE, BY PENICILLINS, 2018-2030 (USD THOUSAND)
  • TABLE 204. UNITED STATES VETERINARY ANTIBIOTICS MARKET SIZE, BY POLYMIXINS, 2018-2030 (USD THOUSAND)
  • TABLE 205. UNITED STATES VETERINARY ANTIBIOTICS MARKET SIZE, BY SULFONAMIDES, 2018-2030 (USD THOUSAND)
  • TABLE 206. UNITED STATES VETERINARY ANTIBIOTICS MARKET SIZE, BY TETRACYCLINES, 2018-2030 (USD THOUSAND)
  • TABLE 207. UNITED STATES VETERINARY ANTIBIOTICS MARKET SIZE, BY TRIMETHOPRIM, 2018-2030 (USD THOUSAND)
  • TABLE 208. UNITED STATES VETERINARY ANTIBIOTICS MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 209. UNITED STATES VETERINARY ANTIBIOTICS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD THOUSAND)
  • TABLE 210. UNITED STATES VETERINARY ANTIBIOTICS MARKET SIZE, BY LIVESTOCK, 2018-2030 (USD THOUSAND)
  • TABLE 211. UNITED STATES VETERINARY ANTIBIOTICS MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
  • TABLE 212. UNITED STATES VETERINARY ANTIBIOTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD THOUSAND)
  • TABLE 213. UNITED STATES VETERINARY ANTIBIOTICS MARKET SIZE, BY STATE, 2018-2030 (USD THOUSAND)
  • TABLE 214. ASIA-PACIFIC VETERINARY ANTIBIOTICS MARKET SIZE, BY CLASS, 2018-2030 (USD THOUSAND)
  • TABLE 215. ASIA-PACIFIC VETERINARY ANTIBIOTICS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2030 (USD THOUSAND)
  • TABLE 216. ASIA-PACIFIC VETERINARY ANTIBIOTICS MARKET SIZE, BY AMPHENICOLS, 2018-2030 (USD THOUSAND)
  • TABLE 217. ASIA-PACIFIC VETERINARY ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORINS, 2018-2030 (USD THOUSAND)
  • TABLE 218. ASIA-PACIFIC VETERINARY ANTIBIOTICS MARKET SIZE, BY FLUOROQUINOLONES, 2018-2030 (USD THOUSAND)
  • TABLE 219. ASIA-PACIFIC VETERINARY ANTIBIOTICS MARKET SIZE, BY MACROLIDES, 2018-2030 (USD THOUSAND)
  • TABLE 220. ASIA-PACIFIC VETERINARY ANTIBIOTICS MARKET SIZE, BY OTHER QUINOLONES, 2018-2030 (USD THOUSAND)
  • TABLE 221. ASIA-PACIFIC VETERINARY ANTIBIOTICS MARKET SIZE, BY PENICILLINS, 2018-2030 (USD THOUSAND)
  • TABLE 222. ASIA-PACIFIC VETERINARY ANTIBIOTICS MARKET SIZE, BY POLYMIXINS, 2018-2030 (USD THOUSAND)
  • TABLE 223. ASIA-PACIFIC VETERINARY ANTIBIOTICS MARKET SIZE, BY SULFONAMIDES, 2018-2030 (USD THOUSAND)
  • TABLE 224. ASIA-PACIFIC VETERINARY ANTIBIOTICS MARKET SIZE, BY TETRACYCLINES, 2018-2030 (USD THOUSAND)
  • TABLE 225. ASIA-PACIFIC VETERINARY ANTIBIOTICS MARKET SIZE, BY TRIMETHOPRIM, 2018-2030 (USD THOUSAND)
  • TABLE 226. ASIA-PACIFIC VETERINARY ANTIBIOTICS MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 227. ASIA-PACIFIC VETERINARY ANTIBIOTICS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD THOUSAND)
  • TABLE 228. ASIA-PACIFIC VETERINARY ANTIBIOTICS MARKET SIZE, BY LIVESTOCK, 2018-2030 (USD THOUSAND)
  • TABLE 229. ASIA-PACIFIC VETERINARY ANTIBIOTICS MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
  • TABLE 230. ASIA-PACIFIC VETERINARY ANTIBIOTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD THOUSAND)
  • TABLE 231. ASIA-PACIFIC VETERINARY ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 232. AUSTRALIA VETERINARY ANTIBIOTICS MARKET SIZE, BY CLASS, 2018-2030 (USD THOUSAND)
  • TABLE 233. AUSTRALIA VETERINARY ANTIBIOTICS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2030 (USD THOUSAND)
  • TABLE 234. AUSTRALIA VETERINARY ANTIBIOTICS MARKET SIZE, BY AMPHENICOLS, 2018-2030 (USD THOUSAND)
  • TABLE 235. AUSTRALIA VETERINARY ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORINS, 2018-2030 (USD THOUSAND)
  • TABLE 236. AUSTRALIA VETERINARY ANTIBIOTICS MARKET SIZE, BY FLUOROQUINOLONES, 2018-2030 (USD THOUSAND)
  • TABLE 237. AUSTRALIA VETERINARY ANTIBIOTICS MARKET SIZE, BY MACROLIDES, 2018-2030 (USD THOUSAND)
  • TABLE 238. AUSTRALIA VETERINARY ANTIBIOTICS MARKET SIZE, BY OTHER QUINOLONES, 2018-2030 (USD THOUSAND)
  • TABLE 239. AUSTRALIA VETERINARY ANTIBIOTICS MARKET SIZE, BY PENICILLINS, 2018-2030 (USD THOUSAND)
  • TABLE 240. AUSTRALIA VETERINARY ANTIBIOTICS MARKET SIZE, BY POLYMIXINS, 2018-2030 (USD THOUSAND)
  • TABLE 241. AUSTRALIA VETERINARY ANTIBIOTICS MARKET SIZE, BY SULFONAMIDES, 2018-2030 (USD THOUSAND)
  • TABLE 242. AUSTRALIA VETERINARY ANTIBIOTICS MARKET SIZE, BY TETRACYCLINES, 2018-2030 (USD THOUSAND)
  • TABLE 243. AUSTRALIA VETERINARY ANTIBIOTICS MARKET SIZE, BY TRIMETHOPRIM, 2018-2030 (USD THOUSAND)
  • TABLE 244. AUSTRALIA VETERINARY ANTIBIOTICS MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 245. AUSTRALIA VETERINARY ANTIBIOTICS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD THOUSAND)
  • TABLE 246. AUSTRALIA VETERINARY ANTIBIOTICS MARKET SIZE, BY LIVESTOCK, 2018-2030 (USD THOUSAND)
  • TABLE 247. AUSTRALIA VETERINARY ANTIBIOTICS MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
  • TABLE 248. AUSTRALIA VETERINARY ANTIBIOTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD THOUSAND)
  • TABLE 249. CHINA VETERINARY ANTIBIOTICS MARKET SIZE, BY CLASS, 2018-2030 (USD THOUSAND)
  • TABLE 250. CHINA VETERINARY ANTIBIOTICS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2030 (USD THOUSAND)
  • TABLE 251. CHINA VETERINARY ANTIBIOTICS MARKET SIZE, BY AMPHENICOLS, 2018-2030 (USD THOUSAND)
  • TABLE 252. CHINA VETERINARY ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORINS, 2018-2030 (USD THOUSAND)
  • TABLE 253. CHINA VETERINARY ANTIBIOTICS MARKET SIZE, BY FLUOROQUINOLONES, 2018-2030 (USD THOUSAND)
  • TABLE 254. CHINA VETERINARY ANTIBIOTICS MARKET SIZE, BY MACROLIDES, 2018-2030 (USD THOUSAND)
  • TABLE 255. CHINA VETERINARY ANTIBIOTICS MARKET SIZE, BY OTHER QUINOLONES, 2018-2030 (USD THOUSAND)
  • TABLE 256. CHINA VETERINARY ANTIBIOTICS MARKET SIZE, BY PENICILLINS, 2018-2030 (USD THOUSAND)
  • TABLE 257. CHINA VETERINARY ANTIBIOTICS MARKET SIZE, BY POLYMIXINS, 2018-2030 (USD THOUSAND)
  • TABLE 258. CHINA VETERINARY ANTIBIOTICS MARKET SIZE, BY SULFONAMIDES, 2018-2030 (USD THOUSAND)
  • TABLE 259. CHINA VETERINARY ANTIBIOTICS MARKET SIZE, BY TETRACYCLINES, 2018-2030 (USD THOUSAND)
  • TABLE 260. CHINA VETERINARY ANTIBIOTICS MARKET SIZE, BY TRIMETHOPRIM, 2018-2030 (USD THOUSAND)
  • TABLE 261. CHINA VETERINARY ANTIBIOTICS MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 262. CHINA VETERINARY ANTIBIOTICS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD THOUSAND)
  • TABLE 263. CHINA VETERINARY ANTIBIOTICS MARKET SIZE, BY LIVESTOCK, 2018-2030 (USD THOUSAND)
  • TABLE 264. CHINA VETERINARY ANTIBIOTICS MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
  • TABLE 265. CHINA VETERINARY ANTIBIOTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD THOUSAND)
  • TABLE 266. INDIA VETERINARY ANTIBIOTICS MARKET SIZE, BY CLASS, 2018-2030 (USD THOUSAND)
  • TABLE 267. INDIA VETERINARY ANTIBIOTICS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2030 (USD THOUSAND)
  • TABLE 268. INDIA VETERINARY ANTIBIOTICS MARKET SIZE, BY AMPHENICOLS, 2018-2030 (USD THOUSAND)
  • TABLE 269. INDIA VETERINARY ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORINS, 2018-2030 (USD THOUSAND)
  • TABLE 270. INDIA VETERINARY ANTIBIOTICS MARKET SIZE, BY FLUOROQUINOLONES, 2018-2030 (USD THOUSAND)
  • TABLE 271. INDIA VETERINARY ANTIBIOTICS MARKET SIZE, BY MACROLIDES, 2018-2030 (USD THOUSAND)
  • TABLE 272. INDIA VETERINARY ANTIBIOTICS MARKET SIZE, BY OTHER QUINOLONES, 2018-2030 (USD THOUSAND)
  • TABLE 273. INDIA VETERINARY ANTIBIOTICS MARKET SIZE, BY PENICILLINS, 2018-2030 (USD THOUSAND)
  • TABLE 274. INDIA VETERINARY ANTIBIOTICS MARKET SIZE, BY POLYMIXINS, 2018-2030 (USD THOUSAND)
  • TABLE 275. INDIA VETERINARY ANTIBIOTICS MARKET SIZE, BY SULFONAMIDES, 2018-2030 (USD THOUSAND)
  • TABLE 276. INDIA VETERINARY ANTIBIOTICS MARKET SIZE, BY TETRACYCLINES, 2018-2030 (USD THOUSAND)
  • TABLE 277. INDIA VETERINARY ANTIBIOTICS MARKET SIZE, BY TRIMETHOPRIM, 2018-2030 (USD THOUSAND)
  • TABLE 278. INDIA VETERINARY ANTIBIOTICS MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 279. INDIA VETERINARY ANTIBIOTICS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD THOUSAND)
  • TABLE 280. INDIA VETERINARY ANTIBIOTICS MARKET SIZE, BY LIVESTOCK, 2018-2030 (USD THOUSAND)
  • TABLE 281. INDIA VETERINARY ANTIBIOTICS MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
  • TABLE 282. INDIA VETERINARY ANTIBIOTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD THOUSAND)
  • TABLE 283. INDONESIA VETERINARY ANTIBIOTICS MARKET SIZE, BY CLASS, 2018-2030 (USD THOUSAND)
  • TABLE 284. INDONESIA VETERINARY ANTIBIOTICS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2030 (USD THOUSAND)
  • TABLE 285. INDONESIA VETERINARY ANTIBIOTICS MARKET SIZE, BY AMPHENICOLS, 2018-2030 (USD THOUSAND)
  • TABLE 286. INDONESIA VETERINARY ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORINS, 2018-2030 (USD THOUSAND)
  • TABLE 287. INDONESIA VETERINARY ANTIBIOTICS MARKET SIZE, BY FLUOROQUINOLONES, 2018-2030 (USD THOUSAND)
  • TABLE 288. INDONESIA VETERINARY ANTIBIOTICS MARKET SIZE, BY MACROLIDES, 2018-2030 (USD THOUSAND)
  • TABLE 289. INDONESIA VETERINARY ANTIBIOTICS MARKET SIZE, BY OTHER QUINOLONES, 2018-2030 (USD THOUSAND)
  • TABLE 290. INDONESIA VETERINARY ANTIBIOTICS MARKET SIZE, BY PENICILLINS, 2018-2030 (USD THOUSAND)
  • TABLE 291. INDONESIA VETERINARY ANTIBIOTICS MARKET SIZE, BY POLYMIXINS, 2018-2030 (USD THOUSAND)
  • TABLE 292. INDONESIA VETERINARY ANTIBIOTICS MARKET SIZE, BY SULFONAMIDES, 2018-2030 (USD THOUSAND)
  • TABLE 293. INDONESIA VETERINARY ANTIBIOTICS MARKET SIZE, BY TETRACYCLINES, 2018-2030 (USD THOUSAND)
  • TABLE 294. INDONESIA VETERINARY ANTIBIOTICS MARKET SIZE, BY TRIMETHOPRIM, 2018-2030 (USD THOUSAND)
  • TABLE 295. INDONESIA VETERINARY ANTIBIOTICS MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 296. INDONESIA VETERINARY ANTIBIOTICS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD THOUSAND)
  • TABLE 297. INDONESIA VETERINARY ANTIBIOTICS MARKET SIZE, BY LIVESTOCK, 2018-2030 (USD THOUSAND)
  • TABLE 298. INDONESIA VETERINARY ANTIBIOTICS MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
  • TABLE 299. INDONESIA VETERINARY ANTIBIOTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD THOUSAND)
  • TABLE 300. JAPAN VETERINARY ANTIBIOTICS MARKET SIZE, BY CLASS, 2018-2030 (USD THOUSAND)
  • TABLE 301. JAPAN VETERINARY ANTIBIOTICS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2030 (USD THOUSAND)
  • TABLE 302. JAPAN VETERINARY ANTIBIOTICS MARKET SIZE, BY AMPHENICOLS, 2018-2030 (USD THOUSAND)
  • TABLE 303. JAPAN VETERINARY ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORINS, 2018-2030 (USD THOUSAND)
  • TABLE 304. JAPAN VETERINARY ANTIBIOTICS MARKET SIZE, BY FLUOROQUINOLONES, 2018-2030 (USD THOUSAND)
  • TABLE 305. JAPAN VETERINARY ANTIBIOTICS MARKET SIZE, BY MACROLIDES, 2018-2030 (USD THOUSAND)
  • TABLE 306. JAPAN VETERINARY ANTIBIOTICS MARKET SIZE, BY OTHER QUINOLONES, 2018-2030 (USD THOUSAND)
  • TABLE 307. JAPAN VETERINARY ANTIBIOTICS MARKET SIZE, BY PENICILLINS, 2018-2030 (USD THOUSAND)
  • TABLE 308. JAPAN VETERINARY ANTIBIOTICS MARKET SIZE, BY POLYMIXINS, 2018-2030 (USD THOUSAND)
  • TABLE 309. JAPAN VETERINARY ANTIBIOTICS MARKET SIZE, BY SULFONAMIDES, 2018-2030 (USD THOUSAND)
  • TABLE 310. JAPAN VETERINARY ANTIBIOTICS MARKET SIZE, BY TETRACYCLINES, 2018-2030 (USD THOUSAND)
  • TABLE 311. JAPAN VETERINARY ANTIBIOTICS MARKET SIZE, BY TRIMETHOPRIM, 2018-2030 (USD THOUSAND)
  • TABLE 312. JAPAN VETERINARY ANTIBIOTICS MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 313. JAPAN VETERINARY ANTIBIOTICS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD THOUSAND)
  • TABLE 314. JAPAN VETERINARY ANTIBIOTICS MARKET SIZE, BY LIVESTOCK, 2018-2030 (USD THOUSAND)
  • TABLE 315. JAPAN VETERINARY ANTIBIOTICS MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
  • TABLE 316. JAPAN VETERINARY ANTIBIOTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD THOUSAND)
  • TABLE 317. MALAYSIA VETERINARY ANTIBIOTICS MARKET SIZE, BY CLASS, 2018-2030 (USD THOUSAND)
  • TABLE 318. MALAYSIA VETERINARY ANTIBIOTICS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2030 (USD THOUSAND)
  • TABLE 319. MALAYSIA VETERINARY ANTIBIOTICS MARKET SIZE, BY AMPHENICOLS, 2018-2030 (USD THOUSAND)
  • TABLE 320. MALAYSIA VETERINARY ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORINS, 2018-2030 (USD THOUSAND)
  • TABLE 321. MALAYSIA VETERINARY ANTIBIOTICS MARKET SIZE, BY FLUOROQUINOLONES, 2018-2030 (USD THOUSAND)
  • TABLE 322. MALAYSIA VETERINARY ANTIBIOTICS MARKET SIZE, BY MACROLIDES, 2018-2030 (USD THOUSAND)
  • TABLE 323. MALAYSIA VETERINARY ANTIBIOTICS MARKET SIZE, BY OTHER QUINOLONES, 2018-2030 (USD THOUSAND)
  • TABLE 324. MALAYSIA VETERINARY ANTIBIOTICS MARKET SIZE, BY PENICILLINS, 2018-2030 (USD THOUSAND)
  • TABLE 325. MALAYSIA VETERINARY ANTIBIOTICS MARKET SIZE, BY POLYMIXINS, 2018-2030 (USD THOUSAND)
  • TABLE 326. MALAYSIA VETERINARY ANTIBIOTICS MARKET SIZE, BY SULFONAMIDES, 2018-2030 (USD THOUSAND)
  • TABLE 327. MALAYSIA VETERINARY ANTIBIOTICS MARKET SIZE, BY TETRACYCLINES, 2018-2030 (USD THOUSAND)
  • TABLE 328. MALAYSIA VETERINARY ANTIBIOTICS MARKET SIZE, BY TRIMETHOPRIM, 2018-2030 (USD THOUSAND)